# Botulinum Toxin Type A in Diabetic Peripheral Neuropathy

> **NCT05296759** · PHASE4 · COMPLETED · sponsor: **Alexandria University** · enrollment: 30 (actual)

## Conditions studied

- Diabetic Neuropathies

## Interventions

- **DRUG:** botulinum toxin A
- **DRUG:** Gabapentin
- **DRUG:** Duloxetine

## Key facts

- **NCT ID:** NCT05296759
- **Lead sponsor:** Alexandria University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-01
- **Primary completion:** 2021-11-01
- **Final completion:** 2022-03-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05296759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05296759, "Botulinum Toxin Type A in Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05296759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*